FIELD: biotechnology.
SUBSTANCE: what is presented is a chimeric antigenic receptor (CAR) designed for depletion of CAR-targeted immune cells. CAR contains an extracellular binding domain which contains scFv formed by a VH chain and a VL chain, CD8 alpha hinge, a transmembrane domain containing a transmembrane region/regions CD8 alpha, and an intracellular domain comprising a CD3 zeta signal domain and a costimulatory domain of 4-1BB. Said extracellular binding domain contains at least one MAt-specific epitope. Invention also relates to production of CAR, to production and use of a constructed T-cell or NK-cell expressing on its cell surface CAR under the invention.
EFFECT: invention provides effective MAt-directed depletion of T-cells expressing said CAR.
30 cl, 22 dwg, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CLL1-SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGENIC RECEPTORS (SCCAR) FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2731543C2 |
| METHODS FOR PRODUCING ALLOGENIC T-CELLS WITH CAR | 2020 |
|
RU2828787C2 |
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B-CELLS | 2016 |
|
RU2706582C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| THERAPEUTIC ANTIBODIES AND THEIR APPLICATION | 2016 |
|
RU2722381C2 |
| COMBINATION THERAPY FOR THE TREATMENT OF BCMA-RELATED CANCER AND AUTOIMMUNE DISORDERS | 2018 |
|
RU2799762C2 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-T CELLS | 2020 |
|
RU2762942C1 |
| ANTIBODIES AND CHIMERIC ANTIGENIC RECEPTORS SPECIFIC TO CD19 | 2015 |
|
RU2741105C2 |
| CD33-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2701341C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR BCMA AND THEIR USE | 2019 |
|
RU2785658C2 |
